Boiron (FRA:BON) 5-Year EBITDA Growth Rate : -11.80% (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Boiron 5-Year EBITDA Growth Rate?

Boiron's EBITDA per Share for the six months ended in Jun. 2024 was €0.94.

During the past 12 months, Boiron's average EBITDA Per Share Growth Rate was -36.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -11.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -11.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Boiron was 43.10% per year. The lowest was -22.10% per year. And the median was 1.30% per year.

Competitive Comparison of Boiron's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Boiron's 5-Year EBITDA Growth Rate falls into.

Boiron 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Boiron (FRA:BON) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Boiron 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Boiron's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BOIRF:USA 0DTF:UK BOI:France

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.